The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer

Title: The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer

Volume: 4 Issue: 1

Author(s): Masao Takei, Akemi Umeyama and Je-Jung Lee

Affiliation:

Keywords: Terpene compounds, cancer immunotherapy, dendritic cells, IL-12, Toll-like receptor (TLR)

Abstract: Dendritic Cells (DC) play a pivotal role in the initiation of T-cell-mediated immune responses, making them an attractive cellular adjuvant for use in cancer vaccines. The interaction of T cell with DC is crucial for directing T cell differentiation towards the Th1, Th2 or Th17 type, and several factors determining the direction of the T cell polarization. IL-12 plays a central role in the immune system, not only by augmenting the cytotoxic activity of T cells and NK cells and regulating IFN-γ production, but also by the capacity of IL-12 to promote the development of Th1. Some plant-derived terpenes regulate differentiation of DC from human monocytes. Terpene compounds-primed DC enhances the differentiation of naive T cell towards the Th1 type, which is dependent on IL-12 secretion. Some patents on terpene compounds, which may lead to the development of effective immunotherapy for cancer, are also discussed in the review.

Cite this article as:

Takei Masao, Umeyama Akemi and Lee Je-Jung, The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2010; 4 (1) . https://dx.doi.org/10.2174/187221410790226783